Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials
{{output}}
Background: The development of personalized approaches in psoriatic arthritis (PsA) is challenging due to unclear patient phenotypes and trajectories. Machine learning (ML) could help to identify homogeneous patient groups. The o... ...
